Upcoming CME

Topic: “Clinical Practice Implications  of the NRG Oncology B51-RTOG 1304  Phase III Trial  Evaluating  Omission of Regional Nodal Irradiation  in  Axillary Node Positive Breast Cancer  Down-staged to Node Negative  by Neoadjuvant Chemotherapy”

Presenter: Dr. Julia White

Date: Wednesday September 17th

Time: 5:30pm-6:30pm ET

Learning Objectives:  

1. Recognize the rationale and evidence supporting the development, design and primary endpoints for the  B51-1304 Phase III randomized trial.
2. Understand the clinical trial primary and secondary endpoint results and appreciate the strength  and limitations of these findings. 
3. Identify the clinical application and implication of the findings from B51-1304   and recognize limitations to implementation.

The 5-year results of the B-51 trial showed that regional nodal irradiation can be safely omitted for certain patients who were initially node positive and have a pathologic complete response after neoadjuvant chemotherapy. Among patients who had a mastectomy, post mastectomy radiation can also be safely omitted.

Date: November 28 - 29, 2025

Location: The Westin Harbour Castle, Toronto

This inaugural conference will focus on clinical advancements related to all aspects of breast cancer survivorship and supportive care through a comprehensive, evidence-based framework.